The capture: legal and regulatory certainty is minimal. Retatrutide was never ever to the FDA drug lack checklist (since it was in no way accredited), so compounders giving it function below more tenuous lawful framing than people who managed semaglutide or tirzepatide in the course of the 2023–2024 shortages. Pricing may possibly shift as enforc